A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma

A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma J. San Miguel, J. Bladé, M. Boccadoro, J. Cavenagh, A. Glasmacher, S. Jagannath, S. Lonial, R.Z. Orlowski, P. Sonneveld, H. Ludwig Oncologist 2006; 11: 51-61 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss clinical trial data for treatment with bortezomib monotherapy and bortezomib-based combination therapy in patients with multiple myeloma who have received at least one prior therapy. Discuss the management of the most common adverse events associated with bortezomib, including peripheral neuropathy and thrombocytopenia. Describe prognostic factors in patients with multiple myeloma who have received at least one prior therapy. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 09, 2006 Most Recent Review: May 8, 2007* Most Recent Update: Jan. 09, 2006 Date Credit Expires: Jan. 09, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.